EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT OF OSTEOMYELITIS IN ADULTS

被引:36
作者
MADER, JT
NORDEN, C
NELSON, JD
CALANDRA, GB
机构
[1] AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,PEARL RIVER,NY 10965
[2] UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75230
[3] MERCH SHARP & DOHME LABS,CLIN RES,W POINT,PA
关键词
D O I
10.1093/clind/15.Supplement_1.S155
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cases of osteomyelitis can be divided into four categories: acute hematogenous, vertebral, secondary to a contiguous focus of infection without vascular disease, and secondary to a contiguous focus of infection with vascular disease. Each category may be further divided into acute and chronic forms. Clinical symptoms persisting for greater-than-or-equal-to 10 days correlate roughly with the development of necrotic bone and chronic osteomyelitis. Patients enrolled in clinical trials should generally be greater-than-or-equal-to 12 years of age. Prior antimicrobial treatment does not exclude patients if the culture of a bone sample obtained at the time of enrollment yields pathogenic bacteria. Randomized, double-blind, active-control comparative studies are encouraged. Clinical outcome should be assessed during therapy and within 5-9 days, 4-6 weeks, and 11-13 months after completion of therapy. In the final assessment, clinical appraisal is paramount.
引用
收藏
页码:S155 / S161
页数:7
相关论文
共 5 条